TW201920165A - 氮吲哚化合物作為組蛋白甲基轉移酶抑制劑 - Google Patents

氮吲哚化合物作為組蛋白甲基轉移酶抑制劑 Download PDF

Info

Publication number
TW201920165A
TW201920165A TW107119935A TW107119935A TW201920165A TW 201920165 A TW201920165 A TW 201920165A TW 107119935 A TW107119935 A TW 107119935A TW 107119935 A TW107119935 A TW 107119935A TW 201920165 A TW201920165 A TW 201920165A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
group
compound
compound according
Prior art date
Application number
TW107119935A
Other languages
English (en)
Chinese (zh)
Inventor
哲 柳
明 余
馬努維拉 則卡內拉
喆 李
Original Assignee
美商全球血液治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商全球血液治療公司 filed Critical 美商全球血液治療公司
Publication of TW201920165A publication Critical patent/TW201920165A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW107119935A 2017-06-09 2018-06-08 氮吲哚化合物作為組蛋白甲基轉移酶抑制劑 TW201920165A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517410P 2017-06-09 2017-06-09
US62/517,410 2017-06-09

Publications (1)

Publication Number Publication Date
TW201920165A true TW201920165A (zh) 2019-06-01

Family

ID=62779058

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107119935A TW201920165A (zh) 2017-06-09 2018-06-08 氮吲哚化合物作為組蛋白甲基轉移酶抑制劑

Country Status (11)

Country Link
US (2) US11111243B2 (enExample)
EP (1) EP3634962B1 (enExample)
JP (1) JP7225125B2 (enExample)
CN (1) CN110997671A (enExample)
AR (1) AR112192A1 (enExample)
BR (1) BR112019025770A2 (enExample)
ES (1) ES2949402T3 (enExample)
IL (1) IL271066A (enExample)
MX (1) MX2019014759A (enExample)
TW (1) TW201920165A (enExample)
WO (1) WO2018226998A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.
JP7749679B2 (ja) * 2021-02-05 2025-10-06 シンノハブ ファーマシューティカル カンパニー,リミティド プラスミン阻害剤、その製造方法およびその適用
CN114394971B (zh) * 2022-01-24 2023-01-31 云南大学 一种吲哚咔唑类化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2402549A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
RU2532135C2 (ru) 2007-02-22 2014-10-27 Зингента Партисипейшнс Аг Производные иминопиридина и их применение в качестве микробиоцидов
AU2008343932B2 (en) * 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PL2364983T3 (pl) 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
US9168247B2 (en) * 2010-06-25 2015-10-27 Facultes Universitaires Notre Dame De La Paix Beta carboline derivatives useful in the treatment of proliferative disorders
TW201236880A (en) 2011-03-11 2012-09-16 Primax Electronics Ltd Sheet feeding apparatus
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US9284272B2 (en) 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
US10407423B2 (en) 2015-11-16 2019-09-10 Fundación Para La Investigación Médica Aplicada Compounds as inhibitors of DNA methyltransferases
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.

Also Published As

Publication number Publication date
AR112192A1 (es) 2019-10-02
JP2020523315A (ja) 2020-08-06
JP7225125B2 (ja) 2023-02-20
IL271066A (en) 2020-01-30
CN110997671A (zh) 2020-04-10
EP3634962A1 (en) 2020-04-15
EP3634962B1 (en) 2023-05-24
WO2018226998A1 (en) 2018-12-13
US20180354947A1 (en) 2018-12-13
ES2949402T3 (es) 2023-09-28
US20210371417A1 (en) 2021-12-02
MX2019014759A (es) 2020-02-12
US11111243B2 (en) 2021-09-07
BR112019025770A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
TWI826416B (zh) 趨化介素受體調節劑及其用途
EP3452453B1 (en) Modulators of the integrated stress pathway
US11046699B2 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
US10246462B2 (en) Chemokine receptor modulators and uses thereof
EP3452456A1 (en) Modulators of the integrated stress pathway
WO2018022992A1 (en) Chemokine receptor modulators and uses thereof
US11254651B2 (en) Histone methyltransferase inhibitors
EP3668863B1 (en) Tricyclic compounds as histone methyl-transferase inhibitors
US20210371417A1 (en) Azaindole compounds as histone methyltransferase inhibitors
TW202406902A (zh) 趨化介素受體調節劑及其用途
CA3235013A1 (en) Hypoxia inducible factor-2(alpha) inhibitors for the treatment of bladder cancer
US20250320204A1 (en) 7-aza bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
OA19439A (en) Azaindole compounds as histone methyltranferase inhibitors.
OA19495A (en) Tricyclic compounds as Histone Methyltransferase inhibitors.